Findings

What do systematic reviews say?

1,655 questions · 1,751 findings · 147 reviews · Pain, Palliative and Supportive Care

Sort:Best matchNewestHighest certainty Download CSV

No studies found 361 · 20.6%GRADE not reported 87 · 5%Very low 625 · 35.7%Low 367 · 21%Moderate 232 · 13.2%High 79 · 4.5%

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

fosnetupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Very low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

aprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Very low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

rolapitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

aprepitant + palonosetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

netupitant + palonosetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

rolapitant + granisetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
High

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

Palonosetron (0 RCTs; 0 participants) · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

aprepitant + granisetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

aprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

azasetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

fosaprepitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

aprepitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

casopitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: serious adverse events (MEC) when vs treatment with granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: serious adverse events (MEC) when vs treatment with granisetron

rolapitant + granisetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1344 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

aprepitant + ramosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low